Morgan Stanley Issues Pessimistic Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock Price

Halozyme Therapeutics (NASDAQ:HALO) had its price target cut by stock analysts at Morgan Stanley from $96.00 to $93.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price would indicate a potential upside of 32.80% from the company’s current price.

Several other equities research analysts also recently commented on the stock. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $80.67.

Halozyme Therapeutics Stock Down 1.3%

HALO stock opened at $70.03 on Tuesday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 3.66. Halozyme Therapeutics has a 12 month low of $47.50 and a 12 month high of $82.22. The firm has a market cap of $8.31 billion, a PE ratio of 25.19, a P/E/G ratio of 0.29 and a beta of 0.89. The firm has a 50 day simple moving average of $65.71 and a 200 day simple moving average of $68.63.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the prior year, the firm earned $1.11 earnings per share. The business’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts forecast that Halozyme Therapeutics will post 7.68 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the transaction, the director directly owned 38,498 shares in the company, valued at approximately $2,443,853.04. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $49,322,187.20. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 120,482 shares of company stock worth $8,200,842. 2.50% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Root Financial Partners LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth $25,000. Larson Financial Group LLC lifted its holdings in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the period. Richardson Financial Services Inc. lifted its holdings in shares of Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 198 shares during the period. Finally, Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 265 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme beat Q1 estimates, with revenue rising about 42% year over year to $376.7 million and EPS coming in above expectations, helping support investor confidence in the company’s growth outlook. Article Title
• Positive Sentiment: The company also highlighted a new $1 billion share repurchase authorization and reiterated full-year guidance, which can be viewed as a signal of management confidence and a potential support for the share price. Article Title
• Positive Sentiment: Halozyme announced a global collaboration and license agreement with GSK for its ENHANZE drug-delivery technology, potentially expanding its long-term royalty stream if partnered programs progress. Article Title
• Neutral Sentiment: Morgan Stanley trimmed its price target on Halozyme to $93 from $96, but kept an overweight rating, so the note was not a major negative for the stock. Article Title
• Negative Sentiment: CEO Helen Torley disclosed two recent stock sales totaling 30,000 shares under a pre-arranged 10b5-1 plan, which may weigh on sentiment even though the trades were planned in advance. Article Title

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.